trending Market Intelligence /marketintelligence/en/news-insights/trending/J4YJQSwa5_vxKUqtFIXUDA2 content esgSubNav
In This List

Patent and Trademark Office OKs MediWound patent for connective tissue disease

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Patent and Trademark Office OKs MediWound patent for connective tissue disease

The U.S. Patent and Trademark Office granted a patent for MediWound Ltd.'s proprietary injectable bromelain solution, MWPC003, for the treatment of connective tissue diseases.

MWPC003 is an investigational sterile injectable solution containing a mixture of the same pharmaceutical-grade proteolytic enzymes used in the company's burn debridement treatment, Nexobrid, which is approved in Europe and other locations.

The patent provides protection for the drug in the treatment of a variety of connective tissue diseases, such as Dupuytren's contracture, Peyronie's disease and scar treatment, among others.